Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
fell 7.1% in the afternoon session after the company trimmed the upper end of its 2025 revenue forecast, citing a delay in vaccine shipments. The company pointed to a delay in vaccine deliveries to the United Kingdom, which it pushed into the first quarter of 2026. This news overshadowed second-quarter results that beat Wall Street expectations. For the quarter, Moderna's revenue dropped about 41% from the previous year to $142 million, driven by lower sales of its COVID-19 vaccine. Despite the revenue decline, the company successfully narrowed its net loss as its cost-cutting measures took effect. Adding to the pressure, Moderna also announced plans to reduce its workforce by 10% and confirmed a delay in the U.S. approval for its combined COVID-flu vaccine until 2026.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
The appointment of Wayne DeVeydt as CFO comes amid an operational reset at UnitedHealth, following a sharp downgrade in its 2025 earnings outlook and a more than 50% drop in its stock price this year.
UnitedHealth Group Inc. (NYSE: UNH) shares are trading lower Thursday, after Baird downgraded the stock to Underperform and slashed its price target from $312 to $198.
President Donald Trump has announced a new private health tracking system, aimed at streamlining patient access to health records and wellness monitoring.
Shares of medical device company Penumbra (NYSE:PEN)
jumped 11.8% in the afternoon session after the company reported impressive second-quarter financial results that surpassed analyst expectations and raised its full-year revenue forecast. The company posted revenue of $339.5 million, a 13.4% increase year-over-year, which beat the consensus estimate of $327.77 million. Earnings per share also came in strong at $0.86, topping expectations of $0.83. This growth was primarily fueled by its U.S. Thrombectomy business, which involves procedures to remove blood clots and saw a 22.6% revenue jump. The embolization segment, which deals with blocking blood flow for treatment, also performed well. Bolstered by this strong performance, Penumbra lifted its full-year 2025 revenue guidance, signaling confidence in its continued growth trajectory.
While BofA sees long-term upside for UnitedHealth, it has applied a lower multiple due to near-term uncertainty around Medicare Advantage and OptumHealth margins.
Healthcare company, UnitedHealth Group Inc. (NYSE: UNH), says that it will drop 600,000 Medicare Advantage members and launch a sweeping operational overhaul after being blindsided by $6.5 billion in unanticipated medical costs.
UnitedHealth’s short-term margin challenges are steep, but the company’s strategic leadership changes and long-term earnings forecast suggest a possible rebound by 2026.
A number of stocks fell in the afternoon session after industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending shockwaves across the health insurance sector.
